Frequency of Influenza-A-H1N1 in Patients with Community-Acquired Pneumonia Admitted to Loghman Hakim Hospital
Novelty in Biomedicine,
Vol. 7 No. 1 (2019),
14 January 2019
AbstractBackground: Here we assessed the incidence of Influenza-A-H1N1-related pneumonia in community-acquired pneumonia (CAP) at Loghman Hakim Hospital, Tehran, Iran.
Materials and Methods: In this prospective study from November 22, 2016, to June 21, 2017, patients with CAP and suspected to seasonal influenza were included. Rapid Antigen test and quantitative real-time PCR assay were performed on samples. P-value < 0.05 was considered significant. In addition, radiologic patterns of them were evaluated.
Results: a total of 29 admitted CAP patients were suspected of seasonal influenza. Two cases out of them were positive for influenza by real-time PCR, similar to result of influenza rapid test. The most common finding in their chest X ray was consolidation in one lobe. None of them vaccinated against influenza. Only nine patients received empiric Oseltamivir treatment. The amount of irrational antibiotic administration was significant.
Conclusion: Despite low statistical numbers, admitted influenza CAP patients did not have unusual symptoms and radiologic patterns. Other results in this study showed need for antibiotic stewardship program and better training about necessity of vaccination.
- Influenza A Virus
- H1N1 Subtype
- Quantitative Real-Time Polymerase Chain Reaction
How to Cite
Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews Immunology. 2012;12(4):269.
Liu X, Jiang S, Fang C, Yang S, Olalere D, Pequignot EC, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer research. 2015;75(17):3596-607.
Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Molecular therapy: the journal of the American Society of Gene Therapy. 2013;21(8):1611-20.
Jiang GM, Xu W, Du J, Zhang KS, Zhang QG, Wang XW, et al. The application of the fibroblast activation protein alpha-targeted immunotherapy strategy. Oncotarget. 2016;7(22):33472-82.
Zhu X, Cai H, Zhao L, Ning L, Lang J. CAR-T cell therapy in ovarian cancer: from the bench to the bedside. Oncotarget. 2017;8(38):64607.
Siegel Rebecca L, Miller Kimberly D, Jemal A. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians. 2018;68(1):7-30.
Yong CSM, Dardalhon V, Devaud C, Taylor N, Darcy PK, Kershaw MH. CAR T-cell therapy of solid tumors. Immunology and Cell Biology. 2016;95:356.
The L. CAR T-cells: an exciting frontier in cancer therapy. Lancet (London, England). 2017;390(10099):1006.
Merckx J, Wali R, Schiller I, Caya C, Gore GC, Chartrand C, et al. Diagnostic accuracy of novel and traditional rapid tests for influenza infection compared with reverse transcriptase polymerase chain reaction: a systematic review and meta-analysis. Annals of internal medicine. 2017;167(6):394-409.
Cheraghi R, Nazari M, Alipour M, Majidi A, Hosseinkhani S. Development of a Targeted anti-HER2 scFv chimeric peptide for gene delivery into HER2-positive breast cancer cells. International journal of pharmaceutics. 2016;515(1):632-43.
Lo A, Wang L-CS, Scholler J, Monslow J, Avery D, Newick K, et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer research. 2015;75(14):2800-10.
Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer journal (Sudbury, Mass). 2014;20(2):151.
Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. mAbs. 2015;7(1):9-14.
Ebert LM, Yu W, Gargett T, Brown MP. Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology. Biochemical Society Transactions. 2018:BST20170178.
Garner EF, Beierle EA. Cancer Stem Cells and Their Interaction with the Tumor Microenvironment in Neuroblastoma. Cancers. 2015;8(1).
Gacerez AT, Sentman CL. T-bet promotes potent antitumor activity of CD4(+) CAR T cells. Cancer gene therapy. 2018;25(5-6):117-28.
Cao Y, Rodgers DT, Du J, Ahmad I, Hampton EN, Ma JS, et al. Design of switchable chimeric antigen receptor T cells targeting breast cancer. Angewandte Chemie. 2016;128(26):7646-50.
Kulemzin S, Kuznetsova V, Mamonkin M, Taranin A, Gorchakov A. CAR T-cell therapy: Balance of efficacy and safety. Molecular Biology. 2017;51(2):237-50.
Laitala AM, Erler JT. Hypoxic signalling in tumour stroma. Frontiers in oncology. 2018;8:189.
Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nature Reviews Clinical Oncology 2016; 13:370.
kasper D, fauci A, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison's principles of internal medicine. 2015.
Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Science Translational Medicine. 2013;5(215):215ra172.
Dengler VL, Galbraith MD, Espinosa JM. Transcriptional regulation by hypoxia inducible factors. Critical reviews in biochemistry and molecular biology. 2014;49(1):1-15.
Apostolopoulos V, Pietersz G, Mckenzie I, Vassilaros S. Pilot phase Iii immunotherapy study in early-stage breast cancer patients using oxidized mannan-muc1. Asia Pacific Journal of Clinical Oncology. 2006; 2:A164.
Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nature reviews Clinical oncology. 2018;15(6):366-81.
Roybal KT, Lim WA. Synthetic immunology: hacking immune cells to expand their therapeutic capabilities. Annual review of immunology. 2017;35:229-53.
Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer cell. 2017;31(3):311-25.
Kasper DL, Fauci AS, Hauser S, et al, editors. Harrison’s principles of internal medicine, 19th ed. New York: The McGraw-Hill Companies. 2015;2(153):803-12.
- Abstract Viewed: 229 times
- PDF Downloaded: 216 times